BA
ESPR

BlackRock Advisors’s Esperion Therapeutics ESPR Stock Holding History

BlackRock Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$92K Sell
7,387
-32
-0.4% -$381 ﹤0.01% 3064
2016
Q3 		$103K Buy
7,419
+951
+15% +$10.8K ﹤0.01% 3004
2016
Q2 		$64K Buy
6,468
+459
+8% +$7.61K ﹤0.01% 3155
2016
Q1 		$102K Hold
6,009
– – ﹤0.01% 2906
2015
Q4 		$134K Sell
6,009
-2,537
-30% -$64K ﹤0.01% 2786
2015
Q3 		$202K Sell
8,546
-3,158
-27% -$198K ﹤0.01% 2722
2015
Q2 		$957K Buy
11,704
+7,102
+154% +$695K ﹤0.01% 1692
2015
Q1 		$426K Buy
4,602
+1,366
+42% +$88.2K ﹤0.01% 2189
2014
Q4 		$131K Buy
3,236
+598
+23% +$18.3K ﹤0.01% 2889
2014
Q3 		$65K Sell
2,638
-601
-19% -$9.55K ﹤0.01% 3201
2014
Q2 		$51K Sell
3,239
-853
-21% -$12.3K ﹤0.01% 3254
2014
Q1 		$62K Sell
4,092
-987
-19% -$15.3K ﹤0.01% 3198
2013
Q4 		$70K Sell
5,079
-113,667
-96% -$1.65M ﹤0.01% 3164
2013
Q3 		$2.24M Buy
+118,746
New +$1.99M ﹤0.01% 1138

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock Advisors's ESPR Position: Q4 2016 in Review

BlackRock Advisors reduced its Esperion Therapeutics (ESPR) stake by 0.43% in Q4 2016, selling an estimated $381 and leaving 7,387 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

BlackRock Advisors first reported a position in ESPR in Q3 2013 and has held it in 14 quarters since. The position peaked at $2.24M in Q3 2013. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

  • BlackRock Advisors held 7,387 shares of Esperion Therapeutics worth $92K as of Q4 2016.
  • BlackRock Advisors sold 32 Esperion Therapeutics shares in Q4 2016, an estimated $381.
  • Esperion Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3064 holding.
  • BlackRock Advisors first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 14 quarters since.
  • BlackRock Advisors's Esperion Therapeutics position peaked at $2.24M in Q3 2013.
  • 99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.